SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 4.90 |
| Enterprise Value ($M) | 4.75 |
| Book Value ($M) | -0.49 |
| Book Value / Share | -0.16 |
| Price / Book | -10.09 |
| NCAV ($M) | -1.14 |
| NCAV / Share | -0.38 |
| Price / NCAV | -4.30 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | -1.39 |
| Return on Equity (ROE) | -2.89 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.66 |
| Current Ratio | 0.66 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 2.12 |
| Assets | 2.77 |
| Liabilities | 3.26 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.02 |
| Operating Income | -11.85 |
| Net Income | -7.44 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -8.61 |
| Cash from Investing | -0.01 |
| Cash from Financing | 6.49 |
(click for more detail) |
|
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 13,170 | 41,561 | 31.69 | |
| 11,109 | 46,557 | 23.86 | |
| 23,384 | 55,175 | 42.38 | |
| 10,097 | 46,541 | 21.69 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| SNSE – Sensei Biotherapeutics, Inc. | SNTI – Senti Biosciences, Inc. |
| SNYR – Synergy CHC Corp. | SPRB – Spruce Biosciences, Inc. |
| SRZN – Surrozen, Inc. |
Financial data and stock pages provided by
Fintel.io